Abatacept inhibits inflammation and onset of rheumatoid arthritis in individuals at high risk (ARIAA): a randomised, international, multicentre, double-blind, placebo-controlled trial
Jürgen Rech, Koray Taşçılar, Melanie Hagen, Arnd Kleyer, Bernhard Manger, Verena Schoenau, Axel J. Hueber, Stefan Kleinert, Xenofon Baraliakos, Jürgen Braun, Uta Kiltz, Martin Fleck, Andrea Rubbert‐Roth, David M. Kofler, Frank Behrens, Martin Feuchtenberger, M. Zaenker, Reinhard Voll, Nils Venhoff, Jens Thiel, Cornelia Glaser, Eugen Feist, Gerd R Burmester, Kirsten Karberg, Johannes Strunk, Juan D. Cañete, Ladislav Šenolt, Mária Filková, Esperanza Naredo, Raquel Largo, Gerhard Krönke, Maria Antonietta D’Agostino, Mikkel Østergaard, Georg Schett
Topics & Concepts
MedicineRheumatoid arthritisAbataceptDouble blindPlaceboInternal medicineRandomized controlled trialArthritisPhysical therapyInflammationAlternative medicinePathologyRituximabLymphomaRheumatoid Arthritis Research and TherapiesSpondyloarthritis Studies and TreatmentsAutoimmune and Inflammatory Disorders Research